A fresh $2.3M pre-seed round has landed for Epitome Therapeutics, the biotechnology company spun out of EMBL in 2025. The funding, backed by XISTA Science Ventures, Caesar Ventures, and Navec Venture Holding, will fuel Epitome's work on precision epigenome editing.
The company is developing CADENCE, a next-generation platform designed to enable the precise and durable calibration of gene dosage without altering the underlying DNA sequence. Epitome aims to establish new therapeutic approaches for diseases driven by dysregulated gene activity, including rare and metabolic disorders.


















